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Abstract
Objective: Thromboelastography (TEG) may provide rapid and clinically important coagulation information in acutely ill patients
with chronic liver disease (CLD). Our objective was to describe the relationship between TEG and conventional coagulation tests
(CCTs), which has not been previously explored in this population. Methods: In acutely ill patients with severe CLD (Child-Pugh
score > 9, category C), we conducted a prospective observational study investigating coagulation assessment as measured by both
CCTs and TEG. We used quantile regression to explore 30 associations between TEG parameters and corresponding CCTs. We
compared TEG and CCT measures of coagulation initiation, clot formation, clot strength, and fibrinolysis. Results:We studied
34 patients on a total of 109 occasions. We observed inconsistent associations between TEG and CCT measures of coagulation
initiation: TEG (citrated kaolin [CK] assay) standard reaction time and international normalized ratio: R2 ¼ 0.117 (P ¼ .044).
Conversely, there were strong and consistent associations between tests of clot formation: TEG (CK) kinetics time and fibri-
nogen: R2 ¼ 0.202 (P < .0001) and TEG (CK) a angle and fibrinogen 0.263 (P < .0001). We also observed strong associations
between tests of clot strength, specifically TEG MA and conventional fibrinogen levels, across all TEG assays: MA (CK) and
fibrinogen: R2 ¼ 0.485 (P < .0001). There were no associations between TEG and D-dimer levels. Conclusions: In acutely ill
patients with CLD, there are strong and consistent associations between TEG measures of clot formation and clot strength and
conventional fibrinogen levels. There are weak and/or inconsistent associations between TEG and all other conventional mea-
sures of coagulation.
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Introduction
The liver is essential to the maintenance of hemostasis.1
Patients with severe chronic liver disease (CLD) who become
acutely unwell may demonstrate several coagulation abnorm-
alities as assessed by conventional coagulation tests (CCTs).
Traditionally, such coagulation abnormalities have been con-
sidered to predict a higher risk of bleeding. However, more
recently it has been proposed that patients with CLD have a
rebalanced coagulation state, whereby such patients are simul-
taneously at increased risk of thrombosis as well as bleeding.2
In addition, a limitation of CCTs is that they are in vitro tests,
which fail to capture the entirety of the in vivo coagulation
system dysfunction in this population.3,4 Despite such concerns
however, CCTs are routinely performed in this patient group
and are commonly used to guide clinical decisions such as
blood product administration.
A potentially more physiologically relevant evaluation of
coagulation status may be provided by thromboelastography
(TEG).5,6 Unlike CCTs, TEG uses the principle of viscoelasti-
city to measure coagulation initiation, clot formation, clot
strength, and fibrinolysis, providing a global assessment of
hemostatic function. Thromboelastography is a rapid, point-
of-care test and is being increasingly used in cardiac surgery,
trauma, and massive transfusions.6,7
We have previously demonstrated that among patients with
decompensated CLD, TEG shows delayed coagulation initia-
tion, weaker clot strength, and impaired fibrinogen function but
also decreased clot lysis.8 However, the relationship between
TEG and CCTs in this population remains unknown. This is
problematic because understanding the associations between
these tests would help define which conventionally measured
variable might be most informative about the coagulation pro-
cess, identify areas of discordance between TEG and conven-
tional measures, and help inform more appropriate coagulation
management in this group.
Accordingly, we performed a prospective, observational
study to describe the associations between CCTs and TEG in
acutely ill patients with severe CLD. Specifically, we assessed
the associations between CCT and TEG parameters in relation
to coagulation initiation, clot formation, clot strength, and
fibrinolysis.
Methods
Study Design, Environment, and Ethics Considerations
We conducted a prospective, observational study to investigate
TEG and CCTs among adult (>18 years) acutely ill patients with
severe CLD (Child-Pugh score >9, category C, duration >12
weeks). Patients were recruited from the intensive care unit
(ICU) or the Victorian state liver transplant service ward between
April and October 2015. The Human Research Ethics Commit-
tees at the Austin Hospital and Monash University approved this
study and waived the need for informed participant consent (Aus-
tin HREC: LNR/15/Austin/70 February 2015, Monash Univer-
sity HREC: CF15/636—2015000291, March 2015).
Details of Data Collected
Patient characteristics, including disease severity (Child-Pugh
criteria), reason for hospital/ICU admission, and ICU Acute
Physiology and Chronic Health Evaluation (APACHE) III
score, were recorded. Admission liver function tests, blood
products, and pro/anticoagulant medications administered dur-
ing the enrollment period were also recorded.
Sample Analysis
Initial TEG and CCTs were performed within 72 hours of
hospital admission by a single investigator and were repeated
at 24-hour increments for up to 7 days or until discharge. Sam-
ples were stored in 2 standard 3.2% citrate solution vials, with 1
vial used for TEG, analyzed by a single, calibrated TEG6S
device (Haemonetics) and the other for CCTs. The TEG6S is
the latest iteration of TEG viscoelastic testing methodology.
The system exposes blood samples to a fixed vibration fre-
quency. The degree of vibration (vertical motion) of the coa-
gulating blood meniscus is measured by an infrared detector to
determine coagulation parameters.9,10 Conversely, the older
TEG5000 model assesses coagulation by measuring shear elas-
ticity of a coagulating blood sample mechanically using a tor-
sion wire connected to a suspended pin within the sample.11
The TEG6S uses greater automation, eliminating the need for
manual sample preparation, minimal pipetting, and calibration,
and allows for multiple assays to be performed simultaneously.
Each TEG sample was recalcified (addition of 20 mL cal-
cium chloride 10%) and analyzed by a 4-channel TEG car-
tridge. These channels are comprised of:
1. Citrated kaolin (CK) assay: contains the coagulation
activator, kaolin, providing standard reaction (R) time,
kinetics (K) time, a angle, maximum amplitude (MA),
and the percentage decrease in amplitude at 30-minute
post-MA (lysis [LY30%]). An illustration of a TEG
trace and these parameters is shown in Figure 1.
2. Rapid-TEG (RT) assay: contains tissue factor (TF) and
kaolin, providing R time, K time, a angle, MA, LY30%,
Figure 1. Thromboelastography (TEG) tracing, depicting rate of
formation and degradation of clot, as well as the reaction time (R),
kinetics time (K), a angle, maximum amplitude (MA) and lysis (LY30%).
Note: LY30% is increased in this image.
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and an activated clotting time (ACT) measuring the
initiation of the clotting phase.
3. Heparinase kaolin (HK) assay: contains kaolin and a
heparin-neutralizing enzyme, providing only R time,
K time, a angle, and MA.
4. Functional fibrinogen (FF) assay: contains kaolin and a
glycoprotein IIb/IIIa antagonist, providing MA based
only on fibrinogen contribution to the thrombus, and
functional fibrinogen level (FLEV), an estimation of
plasma fibrinogen level.
5. Sampling technique and CCT analysis were performed
as previously described (Appendix A).8 Sampling was
performed independent of blood product or pro/antic-
oagulant administration, with results not being used to
influence treatment decisions.
Thromboelastography examines each variable simultane-
ously and in real time. Associations between TEG parameters
and CCTs were grouped according to tests measuring (1) coa-
gulation initiation (TEG R time, ACT, and conventional inter-
national normalized ratio (INR), prothrombin time (PT), and
activated partial thromboplastin time (APTT); (2) clot forma-
tion (TEG K time, a angle, and conventional fibrinogen level);
(3) clot strength (TEG MA and conventional fibrinogen level,
platelet count); and (4) fibrinolysis (TEG LY30% and conven-
tional D-dimer levels).
Statistical Analysis
Analyses were performed using STATA analytical software
(Stata version SE, 13.0). Categorical data are presented as
counts and proportions, and continuous data are presented
as medians with interquartile ranges (IQRs). Nonparametric
statistics were used given the small sample size of this
exploratory analysis. The relationship between each individ-
ual TEG parameter and CCT was investigated using clustered
quantile regression with 500 bootstrap samples, a technique
superior to mean regression for nonparametric data. Clustered
quartile regression deals robustly with outliers and skewing
while controlling for the inflating effect of repeated mea-
sures.12 Quantile regression also generates an association esti-
mate with 95% confidence interval (ie, slope of the regression
line), a pseudo-R2 value (an estimate of the strength of the
association between the variables under examination), and a P
value. We defined a pseudo-R2 value of >0.20 as indicating
excellent goodness of fit, and by extension a “strong” associ-
ation, as per the most conservative convention.13,14 Signifi-
cance was taken to be P <.01 to account for repeated
measures.
Results
Patient Characteristics
A total of 109 paired CCT and TEG samples were obtained
from 34 acutely ill patients with CLD, with a median of 3 (IQR:
1-5) samples per patient. Fourteen (41%) participants were
enrolled from the ICU and 20 (59%) participants from the acute
hepatology wards (Table 1). Infection was the most common
ICU admission diagnosis (n ¼ 7, 50%).
On hospital admission, 34 (100%) patients had deranged
liver functions tests, characterized by hyperbilirubinemia and
Table 1. Patient Demographics, Baseline Liver Function Tests, CCTs
and Blood Products, Vitamin K, and Anticoagulant Administration.a
Demographics
Male 21 (62%)
Age, years old 56 (48-65)
Child-Pugh score 12 (11-12)
Bilirubin 3 (2-3)
Albumin 3 (2-3)
International normalized ratio 2 (1-3)
Ascites 3 (2-3)
Encephalopathy 2 (1-2)
Model end-stage liver disease score 26 (20-36)
Previous liver transplant; total 3
Intensive care unit patients; total 14 (41%)
Ward patients 20 (59%)
Liver function tests Normal
reference
range
Bilirubin, mmol/L 77.5 (50-165) <21
Alanine aminotransferase, units/L 41.5 (28-93) 5-35
Aspartate aminotransferase,
units/L
127.5 (86-178.5) <40
Gamma glutaminase, units/L 62.5 (37-124) <60
Alkaline phosphatase, units/L 146.5 (85-223) 30-110
Albumin, g/L 26.5 (21-32) 35-50
Coagulation tests
Prothrombin time, seconds 19.1 (16-25.6) 11.0-15.0
International normalized ratio 1.8 (1.5-2.5)
Activated partial thromboplastin
time, seconds
43.4 (35.2-50.8) 22-41
Fibrinogen, g/L 1.5 (0.8-3.1) 2.0-4.0
Platelets, 109 cell/L 61 (45.8-95.8) 150-400
D-dimer, mg/L 1.8 (0.8-3.1) <0.5
Blood product n (%) Median
(IQR) units
Cryoprecipitate 4 (12%) 10 (6.5-12)
Packed red blood cells 12 (35%) 2.5 (1-6)
Fresh-frozen plasma 7 (21%) 2 (2-7.5)
Platelets
Standard units 5 (15%) 3 (1.5-4)
Pooled platelets 5 (15%) 1 (1-4)
Medication
Vitamin K (10 mg IV/d) 21 (62%)
Aspirin 1 (3%)
Warfarin 3 (9%)
Enoxaparin 14 (41%)
Heparin
Low (<10 000 units/d) 4 (12%)
High (>10 000 units/d) 4 (12%)
Dextran 1 (3%)
Abbreviations: CCTs, conventional coagulation tests; IV, intravenous; IQR,
interquartile range.
aValues Presented as median (IQR) or percentage, n ¼ 34.
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hypoalbuminemia. The median Child-Pugh score was 12
(IQR: 11-12). The median model for end-stage liver disease
score was 26 (IQR: 20-34). The median APACHE III illness
severity score for the 14 ICU patients was 84 (IQR: 60-90;
Table 1).
Blood Product and Pro/Anticoagulant Administration
Most patients received vitamin K (n ¼ 21, 62%), and most
patients (n ¼ 25, 74%) received some form of anticoagulant
therapy (warfarin: n ¼ 3 [9%]; prophylactic enoxaparin: n ¼
14 [41%]; heparin: n ¼ 8 [24%]). A summary of procoagulant
and anticoagulant medications administered is summarized in
Table 1. Blood products were administered to 15 (44%)
patients during the study. Packed red blood cells were the
most commonly administered product, administered to 12
(35%) patients (median 3 units/patient; Table 1).
Conventional Coagulation Tests Results
Conventional coagulation tests were abnormal in our patient
cohort, characterized by elevated median PT, INR, APTT, and
D-dimer levels and reduced median fibrinogen levels and pla-
telet counts versus normal reference ranges (Table 1).
Thromboelastography Results
Comparing TEG results in the CLD patient cohort versus
normal manufacturer reference ranges, we observed normal
clot initiation (demonstrated by normal R time), poor clot
formation (demonstrated by longer K time and low-normal
alpha angles), decreased clot strength (demonstrated by
reduced MA), and low normal fibrinolysis (measured by
LY30%). These findings were consistent across all TEG
assays (Table 2).
Relationship Between TEG and CCTs
We investigated 30 associations between TEG and CCTs in
total. This included 12 associations between tests measuring
coagulation initiation, 6 between tests measuring clot forma-
tion, 4 between tests measuring clot strength, and 2 between
tests measuring fibrinolysis: A strong association (R2 value
>0.2) was demonstrated in 5 of the 12 associations assessed
between TEG and CCT markers of coagulation initiation (TEG
R time, ACT, and conventional INR, PT, APTT; Table 3).
Similarly, a strong association (R2 value >0.2) was demon-
strated in all associations between TEG and CCT markers of
clot formation (TEG K time, a angle, and conventional fibrino-
gen level; Table 4). We observed a consistent association pat-
tern between TEG markers of clot strength and CCTs with 5 of
the 10 associations being strong (TEG MA and conventional
fibrinogen level, platelet count; Table 5). Consistently, all
strong associations were between TEG parameters and fibrino-
gen level, with no strong associations between TEG parameters
and platelet count. Finally, there were no strong associations
between TEG and CCT markers of fibrinolysis (TEG LY30%
and conventional D-dimer levels; Table 6).
Outcomes
The median (IQR) length of ICU stay was 16 days (3-40); 12
(86%) of 14 patients who required an ICU admission survived.
Median (IQR) length of hospital admission was 22 days (5-91);
29 (85%) patients survived with an overall in-hospital mortality
of 15%.
Discussion
Key Findings
We performed a prospective observational study describing the
relationship between CCTs and TEG in acutely ill patients with
severe CLD. In this cohort of patients, the strongest associa-
tions between TEG and CCTs occurred when measuring clot
formation and clot strength. Strong associations were consis-
tently seen between TEG markers of both clot formation (K
time and a angle) and TEG markers of clot strength (MA), and
conventional fibrinogen levels. Conversely, TEG and CCTs
demonstrated weak and inconsistent associations across all
other parameters, including tests of coagulation initiation, pla-
telet count, and fibrinolysis. Finally, both TEG and CCTs
Table 2. Parameters of TEG in Chronic Liver Disease.a
TEG assay channel
Study cohort,
medianb (IQR)
Normal
reference
range
CK: Citrated kaolin
R time, minutes 6.9 (6.3-8.3) 4.6-9.1
K time, minutes 2.9 (1.7-4) 0.8-2.1
a Angle, degrees 65 (58.7-70.2) 63-78
Maximum amplitude, mm 43.3 (30.4-53.3) 52-69
Lysis, % 0.1 (0-1.1) 0-2.6
RT: rapid TEG
R time, minutes 1.1 (0.6-1.9) 0.3-1.1
K time, minutes 3.3 (1.5-4.9) 0.8-2.7
a angle, degrees 60.3 (48-73.5) 60-78
Maximum amplitude, mm 41.9 (33-54.1) 52-70
Lysis, % 0 (0-0.4) 0-2.2
Activated clotting time, seconds 157.1 (110.3-230.1) 82-152
Heparinase kaolin
R time, minutes 6.4 (5.8-8) 4.3-8.3
K time, minutes 2.7 (1.5-3.6) 0.8-1.9
a angle, degrees 66 (60-72.8) 64.3-77.1
Maximum amplitude, mm 42.9 (35.5-54.1) 52.3-68.9
Functional fibrinogen
Maximum amplitude, mm 12 (4.3-20.5) 15-32
Functional fibrinogen level, mg/dL 219.4 (122-387.7) 278-581
Abbreviations: IQR, interquartile range; K, kinetics; R, reaction; TEG,
thromboelastography.
an ¼ 34.
bStudy cohort median ¼ population median, derived from the mean of each
patient, across all patient samples, in order to appropriately measure central
tendency.
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Table 3. Association Between TEG and Conventional Coagulation Tests for Measurement of Coagulation Initiation.a,b
TEG parameter CCT Pseudo-R2 value P valuec Gradient of slope “association estimate” (95% CI)
R time
Citrated Kaolin assay APTT 0.289 .004 5.42 (1.72 to 9.13)
PT 0.001 .934 0.05 (1.08 to1.18)
INR 0.000 1.000 0.00 (0.10 to 0.10)
Rapid TEG assay APTT 0.048 .327 4.23 (4.23 to 12.69)
PT 0.267 .020 4.33 (0.69 to 7.98)
INR 0.229 .016 0.40 (0.07 to 0.73)
Heparinase assay APTT 0.143 .001 5.32 (2.13 to 8.52)
PT 0.116 .005 2.13 (0.66 to 3.60)
INR 0.098 .006 0.19 (0.05 to 0.33)
Rapid TEG ACT APTT 0.048 .309 0.05 (0.04 to 0.13)
PT 0.267 .020 0.05 (0.01 to 0.09)
INR 0.229 .019 0.00 (0.00 to 0.01)
Abbreviations: APTT, activated partial thromboplastin time; ACT, activated clotting time; CCT, conventional coagulation test; INR, international normalized ratio;
PT, prothrombin time; R, reaction; TEG, thromboelastography.
an ¼ 34.
bExpressed as correlation coefficient, 95% CI, P value, and pseudo-R2 value. All values within 95% CI with +1.96 standard deviations.
cP value ¼ Derived from regression analysis. Significance taken to be P < .01: P value and pseudo-R2 rounded to 3 decimal places, other data to 2 decimal places.
Table 4. Association Between TEG and Conventional Coagulation Tests for Measurement of Clot Formation.a,b
TEG parameter CCT Pseudo-R2 value P valuec Gradient of slope “association estimate” (95% CI)
K time
Citrated Kaolin assay Fib 0.202 .000 0.20 (0.29 to 0.09)
Rapid TEG assay Fib 0.281 .000 0.17 (0.25 to 0.08)
Heparinase assay Fib 0.262 .000 0.20 (0.28 to 0.11)
a Angle
Citrated Kaolin assay Fib 0.263 .000 0.06 (0.04 to 0.09)
Rapid TEG assay Fib 0.406 .000 0.06 (0.05 to 0.07)
Heparinase assay Fib 0.313 .000 0.07 (0.05 to 0.09)
Abbreviations: CCT, conventional coagulation test; Fib, fibrinogen; K, kinetics; TEG, thromboelastography.
an ¼ 34.
bExpressed as correlation coefficient, 95% CI, P value, and pseudo-R2 value. All values within 95% CI with +1.96 standard deviations.
cP value ¼ Derived from regression analysis. Significance taken to be P < .01: P value and pseudo-R2 rounded to 3 decimal places, other data to 2 decimal places.
Table 5. Association Between TEG and Conventional Coagulation Tests for Measurement of Clot Strength.a,b
TEG parameter CCT Pseudo-R2 value P valuec Gradient of slope “association estimate” (95% CI)
Maximum amplitude
Citrated Kaolin assay Plt 0.148 .006 1.95 (0.57 to 3.33)
Fib 0.485 .000 0.06 (0.05 to 0.73)
Rapid TEG assay Plt 0.173 .005 1.97 (0.60 to 3.34)
Fib 0.544 .000 0.06 (0.05 to 0.07)
Heparinase assay Plt 0.158 .006 1.95 (0.56 to 3.34)
Fib 0.517 .000 0.06 (0.05 to 0.07)
Functional fibrinogen assay Plt 0.070 .150 1.71 (0.62 to 4.04)
Fib 0.391 .000 0.06 (0.03 to 0.09)
Estimated fibrinogen level
Functional fibrinogen assay Plt 0.070 .181 0.10 (0.05 to 0.24)
Fib 0.412 .000 0.00 (0.00 to 0.01)
Abbreviations: CCT, conventional coagulation test; Fib, fibrinogen; Plt, platelet; TEG, thromboelastography.
an ¼ 34.
bExpressed as correlation coefficient, 95% CI, P value, and pseudo-R2 value. All values within 95% CI with +1.96 standard deviations.
cP value ¼ Derived from regression analysis. Significance taken to be P < .01: P value and pseudo-R2 rounded to 3 decimal places, other data to 2 decimal places.
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demonstrated a generally hypocoagulable picture in this group,
characterized by slow clot formation and reduced clot strength.
The TEG and CCT markers of fibrinolysis were inconsistent,
with D-dimer being elevated, while TEG demonstrated low
normal fibrinolysis in this patient group.
Relationship With Existing Evidence
Evidence suggests CCTs fail to predict the risk of bleeding
following invasive procedures in patients with CLD.15,16 The
risk of postprocedural bleeding has been repeatedly demon-
strated to be independent of platelet count and INR/PT in this
cohort.17,18 Moreover, there is no strong evidence that PT or
INR predicts spontaneous bleeding in this group.19 Addition-
ally, a 2018 study examining 280 patients with cirrhosis con-
cluded that platelet count does not predict unprovoked major or
minor bleeding in this group.20 Conversely, a 2016 study on
over 1400 patients concluded that hypofibrinogenemia
(defined as fibrinogen levels <200 mg/dL) was associated with
an approximately 6-fold increase in the risk of major sponta-
neous bleeding compared to patients with fibrinogen levels
200 mg/dL.21 As such, the available evidence suggests that
tests measuring clot formation and strength (ie, fibrinogen)
may have greater predictive value for bleeding events than tests
of coagulation initiation/coagulation speed.
When examining the differences in associations between
various TEG assays and CCTs, RT generated different associa-
tions with CCTs for clotting initiation. Also, the FF assay per-
formed differently when measuring clotting strength.
There were weak associations between TEG R time and
conventional PT and INR in both standard CK and HK assays.
Conversely, we observed strong associations between both PT
and INR and TEG R time in the RT assay. We also noted strong
associations between both PT and INR and RT ACT. This trend
was not continued between RT R time and APTT. These data
imply that testing via RT generates a stronger association with
conventional PT and INR than other TEG assays. This may be
due to the presence of TF as a reagent in the RT assay. Emer-
ging evidence suggests that TF is a critical mediator of coagu-
lation in liver disease.22 Moreover, in patients with severe
cirrhosis (Child-Pugh C), observational studies have demon-
strated an increase in circulating TF without a counterbalancing
increase in TF pathway inhibitor.23 The presence of extrinsic
TF in the RT assay may exaggerate this imbalance and subse-
quently more closely relate to PT/INR tests which are also
dependent on the presence of extrinsically added TF.24
Whether the stronger associations between RT and PT/INR are
related to a closer reflection of in vivo coagulation or a result of
the presence of TF as a reagent requires further research. It
should be acknowledged that the pseudo-R2 of the associations
between both PT/INR and both RT R time and ACT were only
slightly >0.2.
While all associations between TEG MA and conventional
fibrinogen levels were strong, the association between func-
tional fibrinogen TEG MA and conventional fibrinogen was
weaker than other TEG MA and fibrinogen associations exam-
ined. Additionally, the association between FLEV and conven-
tional fibrinogen was also weaker than TEG MA and
fibrinogen associations examined. We observed that FF FLEV
estimated higher fibrinogen levels compared to conventional
testing; conventional fibrinogen ¼ 1.5 g/L (0.8-3.1g/L) com-
pared to FLEV ¼ 2.2 (1.2-3.9g/L; Tables 1 and 2). This differ-
ence in absolute fibrinogen value is insufficient to explain the
weaker association between conventional fibrinogen and FF
TEG tests. This unexpected finding has not been demonstrated
by other work to our knowledge and requires further
investigation.
To our knowledge, there is only one other study investigat-
ing the relationship between viscoelastic testing and CCTs in
patients with severe CLD. This study also demonstrated an
association between TEG measures of clot formation and fibri-
nogen estimates and other coagulation studies, however this
study examined the relationship between viscoelastic measures
and specific factor levels and examined a less unwell cohort
(patients with cirrhosis not in ICU) and used rotational throm-
boelastometry (ROTEM) rather than TEG.25
Our study agrees with analysis of TEG and CCTs performed
in other patient groups, which also demonstrated a strong rela-
tionship between TEG MA and conventional fibrinogen
level.26,27 An association between TEG MA and both conven-
tional fibrinogen level and platelet count has also been demon-
strated postpediatric cardiac surgery.28 To our knowledge,
there has been no study comparing TEG and CCTs in patients
with CLD, with the only similar studies in patients undergoing
liver transplantation.29,30
Implications of Study Findings
Firstly, the finding of strong and consistent association between
TEG parameters and traditional fibrinogen level (clot
Table 6. Association Between TEG and Conventional Coagulation Tests for the Measurement of Fibrinolysis.a,b
TEG parameter CCT Pseudo-R2 value P valuec Gradient of slope “association estimate” (95% CI)
Lysis %
Citrate Kaolin assay D-dimer 0.064 0.200 0.38 (0.97 to 0.20)
Rapid TEG assay D-dimer 0.043 0.257 0.59 (1.60 to 0.43)
Abbreviations: CCT, conventional coagulation test; TEG, thromboelastography.
an ¼ 34.
bExpressed as correlation coefficient, 95% CI, P value, and pseudo-R2 value. All values within 95% CI with +1.96 standard deviations.
cP value ¼ Derived from regression analysis. Significance taken to be P < .01: P value and pseudo-R2 rounded to 3 decimal places, other data to 2 decimal places.
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formation and clot strength) is important given that fibrinogen
deficit or dysfunction is related to both increased bleeding risk
and mortality in this patient cohort.2,31 Hypersialylation of the
fibrinogen molecule in this setting may also lead to defective
fibrinogen-to-fibrin conversion possibly underpinning some of
the observed coagulopathy on TEG.32 We demonstrated that
TEG has weak or inconsistent relationships with all conven-
tional tests, with the exception of fibrinogen. This implies that
the TEG FF assay can be used to guide the clinical management
of patients with CLD, given its strong association with conven-
tional fibrinogen levels. To our knowledge, our study is the first
to demonstrate this in this population group.
The poor associations between TEG and CCTs measuring
coagulation initiation imply that such measures in this cohort
remain difficult to interpret and should be used cautiously to
inform clinical decisions, adding to available evidence that
these tests are poorly predictive of bleeding risk, and poorly
reliable in this cohort.33
We demonstrated poor association between TEG and con-
ventional measures of fibrinolysis (characterized by low nor-
mal TEG LY30% and elevated D-dimer levels), which to our
knowledge is the first time this has been demonstrated in this
patient group. D-dimer is a nonspecific marker of fibrin degra-
dation, with elevated levels present in a number of disease
states including thromboembolism, neoplasia, nonspecific
inflammation, or sepsis, with a mild rise in keeping with a
multitude of pathophysiological processes in a critically ill
population.34 While evidence suggests that elevated D-dimer
in the presence of other plasma abnormalities (ie, elevated
tissue plasminogen activator) indicates hyperfibrinolysis and
can predict gastrointestinal bleeding in this population, ele-
vated D-dimer alone provides limited information regarding
an individual’s fibrinolytic state.35,36 Thromboelastography
has been suggested to be superior to conventional methods of
detecting clot lysis in other patient groups.37 Our findings
imply that TEG may provide more information than conven-
tional tests in detecting fibrinolysis abnormalities in patients
with CLD. Emerging evidence suggests primary hyperfibrino-
lysis is an increasingly important pathophysiological process in
CLD resulting in an increased risk of variceal bleeding, having
potentially important implications for coagulation monitoring
in this group.38,39
Our findings may also be partly explained by the role of
factor XIII (FXIII) and its role in clot stabilization. Factor XIII
is being increasingly understood to be an important mediator in
the coagulopathy of liver disease, with low FXIII associated
with more bleeding events and a higher mortality in patients
with severe liver disease.40 Viscoelastic tests, including
ROTEM and TEG, have previously been used to demonstrate
reduced FXIII activity in patients with severe liver disease,
characterized by reduced MA and increased lysis.41,42 The
observed reduced MA and increased clot lysis support existing
literature that suggests low FXIII activity, in addition to abnor-
mal fibrinogen level and platelet count, may have an important
role in mediating coagulation in this patient group. Finally, our
data imply that patients with severe CLD demonstrate a
generally hypocoagulable picture, characterized by slower clot
formation and reduced clot strength, and conflicting, difficult
to interpret fibrinolysis results. By illustrating that prolonged
PT/INR/APTT was not generally associated with a prolonged
reaction (R) time but that reduced fibrinogen level was consis-
tently associated with reduced clot strength, our study demon-
strates how TEG may provide additional coagulation
information to clinicians in this patient group, including for
use in guiding appropriate blood product administration.43
Strengths and Limitations
This study provides a robust, contemporary and comprehensive
assessment of the relationship between CCTs and TEG in a
cohort of acutely ill patients with CLD. We assessed coagula-
tion across multiple modern TEG assays using modern TEG6S
technology, which unlike the previous model, generates 17
parameters across 4 simultaneously executed assay types, as
opposed to 6 parameters generated from a single assay, as in the
previous models (TEG5000, Haemonetics). Additionally, this
is the first study comparing coagulation assessment modalities
(TEG and conventional methods) in this patient group (severe
CLD) using repeated measures, via daily sampling, thus pro-
viding dynamic data in each patient. Finally, these findings
have clinical and pathophysiological implications and provide
novel information for coagulation management.
This study also carries several limitations. It was a non-
interventional, observational study and did not have the capac-
ity to allow outcome-based comparisons to determine the
clinical value of TEG over CCTs or assess TEG as a predictor
of bleeding or thrombosis. Administration of blood products
and anticoagulant medications were confounders in this study.
However, clinicians administered blood products in an attempt
to restore normal coagulation and despite such product admin-
istration, patients with CLD remained coagulopathic. Simi-
larly, around half the patients in this study received
anticoagulant drugs; however, this was controlled for by sensi-
tivity analysis. We acknowledge various treatments (including
but not limited to various types and quantities of blood product
administration, various doses of various pro- and anticoagulant
medication, continuous renal replacement therapy, surgery,
and/or crystalloid administration) may influence TEG and con-
ventional coagulation results. However, understanding the
effect of such therapies on the associations between TEG and
CCTs would require significant multivariate analyses and a
large sample size and is unfortunately beyond the scope of this
observational study. We recognize that TEG is not gold stan-
dard for the assessment of coagulation in this patient group;
however a number of studies have shown that TEG may be
superior to CCTs in assessing bleeding and clotting risk in
other patient groups.43-45 Finally, this study examined all
patients presenting with severe CLD and did not assess the
differential impact of any specific underlying etiology. How-
ever, our study aimed to assess the coagulation state of a het-
erogeneous population of acutely ill patients with CLD.
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Conclusion
In acutely ill patients with CLD, strong associations were
observed between TEG measures of both clot formation and
clot strength, and conventional fibrinogen level tests. However,
weak or inconsistent associations were observed between TEG/
CCTs measuring coagulation initiation (ie, TEG R time and
INR/APTT/PT), TEG and conventional platelet count, and
measures of fibrinolysis (TEG LY30% and conventional D-
dimer). This supports available evidence that measures of clot-
ting initiation and speed are difficult to interpret in this cohort,
while TEG MA and conventional fibrinogen may be more
reliable. Additionally, we observed that both TEG and CCTs
demonstrated a hypocoagulable picture in this patient group,
characterized by slower clot formation and reduced clot
strength. Our findings provide novel information on the rela-
tionship between TEG and CCTs and provides rationale for
further studies investigating the role of TEG in predicting
bleeding and guiding clinical decision-making in this in this
coagulopathy-prone, high-risk population.
Appendix A
Method of Conventional Coagulation Test Sample
Analysis
Activated partial thromboplastin time was measured via a clot-
based assay using purified phospholipid and micronized silica
activator (Triniclot HS reagent, TCOAG). Prothrombin time
and international normalized ratio (INR) were measured using
platelet poor plasma collected in 3.2% citrate anticoagulant,
analyzed by a clot-based assay using recombinant TF relipi-
dated in a synthetic phospholipid blend combined with calcium
chloride (PT-Recombiplastin reagent, Instrumentation Labora-
tory). From this, INR was generated using the following
equation:
INR ¼ (PT/mean PT)  ISI. PT: prothrombin time; ISI:
International Sensitivity Index, provided by Instrumentation
Laboratory (IL), manufacturers of the PT reagent, PT Recom-
biplastin. The ISI is referenced by IL to an international stan-
dard. The mean PT and ISI values currently used at Austin
Pathology for PT-Recombiplastin lot number N0741093 are
10.6 (seconds) and 0.97, respectively. Fibrinogen level was
estimated using derived fibrinogen, from absorbance during
the PT clot-based assay relative to a calibrator (PT-
Recombiplastin reagent, Instrumentation Laboratory). When
derived fibrinogen yielded a result less than 2.0 g/L, a Clauss
fibrinogen was measured, which is more accurate below this
level. The 2 results show strong correlation within the normal
reference interval. D-dimer was measured using latex-
enhanced immunoassay (D-dimer HS reagent, Instrumentation
Laboratory). Finally, platelet count was taken from the last
available routine full blood count recorded as per standard care,
rather than at time of sampling. This was in order to both
minimize the number of additional blood vials collected, mak-
ing the study more ethically amenable and to simultaneously
negate the impact of citrate on platelet function, known to
unpredictably underestimate platelet count. For this purpose,
routine full blood count was performed using a Sysmex
XE5000 analyser (Sysmex corporation), which utilizes impe-
dance methodology using hydrodynamic focusing.
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